Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $54.2 million.

  • Axsome Therapeutics' Change in Accured Expenses rose 919.11% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 144.85%. This contributed to the annual value of $56.1 million for FY2024, which is 53.81% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Change in Accured Expenses of $54.2 million as of Q3 2025, which was up 152.26% from $21.5 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Change in Accured Expenses ranged from a high of $54.2 million in Q3 2025 and a low of -$8.4 million during Q1 2024.
  • In the last 3 years, Axsome Therapeutics' Change in Accured Expenses had a median value of $11.4 million in 2023 and averaged $15.4 million.
  • Per our database at Business Quant, Axsome Therapeutics' Change in Accured Expenses slumped by 217.81% in 2024 and then spiked by 919.11% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Change in Accured Expenses (Quarterly) stood at $13.2 million in 2022, then dropped by 13.91% to $11.4 million in 2023, then spiked by 125.95% to $25.7 million in 2024, then spiked by 919.11% to $54.2 million in 2025.
  • Its last three reported values are $54.2 million in Q3 2025, $21.5 million for Q2 2025, and $818,000 during Q1 2025.